Company Profile

Ulisse BioMed S.p.A. is a biotechnology company specialized in developing medical diagnostics, theranostics and therapeutics solutions. The company has 3 technology platforms, namely, Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics).
Net sales are distributed geographically as follows: Italy (88.6%), America (4.6%), Europe (6.1%) and other (0.7%).


Source: Cofisem - Last Update: 2025-11-18

Key Executives
Chief Executive Officer Nicola Basile
Head of Investor Relations Gabriele Salaris


Source: Cofisem - Last Update: 2025-11-18

Key Figures
Millenium 2024 2023 2022 2021 2020
Net sales 768 66 138 277 429
Consumed purchases 542 316 328 117 141
Labour costs 1,772 497 330 141 111
Operating profit -5,911 -4,796 -1,306 -604 224
Income tax 0 0 0 0 2
Net income -5,940 -4,796 -1,308 -604 222
Net income (Group share) -5,940 -4,796 -1,308 -604 222
Fiscal year end 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards Local GAAP Local GAAP Local GAAP Local GAAP Local GAAP

Source: Cofisem - Last Update: 2025-11-18

Shareholder information
Free float 31.6 %
Other shareholders 19.7 %
Stefano Lo Priore 15.19 %
Alberto Amati 10.92 %
Algebris Investments Limited 6.94 %
Good Harvest Ventures 6.33 %
Locorian s.s. 3.61 %
Copernico Innovazione S.r.l. 3.38 %
Bantess s.s. 1.37 %
Bruna Marini 0.95 %
Matteo Petti 0.01 %


Source: Cofisem - Last Update: 2025-11-18

Please contact MyQuestion.Italy@euronext.com for Company Profile support.

Quotazioni, Book, Dividendi, Documenti Societari, Corporate Governance, Internal Dealing di Ulisse Biomed


The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.


You will be redirected in five seconds.